Ascletis Pharma, Inc. (HK:1672)
:1672
Want to see HK:1672 full AI Analyst Report?
1672 Stock Chart & Stats
HK$18.48
HK$0.09(3.03%)
At close: 4:00 PM EST
HK$18.48
HK$0.09(3.03%)
Day’s Range― - ―
52-Week RangeHK$8.29 - HK$19.86
Previous CloseN/A
Volume2.91M
Average Volume (3M)8.30M
Market Cap
HK$10.63B
Enterprise ValueHK$11.53B
Total Cash (Recent Filing)HK$1.90B
Total Debt (Recent Filing)HK$5.16M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Aug 24, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding1,068,455,100
10 Day Avg. Volume6,104,199
30 Day Avg. Volume8,303,348
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)5.14
Price to Sales (P/S)4905.97
P/FCF Ratio-30.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$20.17Price Target Upside9.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.44
Revenue Forecast (FY)HK$804.38M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Solvency CushionVery low debt levels give the company durable solvency flexibility, reducing near-term default risk and preserving the ability to raise capital or sustain R&D spend without immediate refinancing pressure. This structural balance-sheet strength supports multi‑month program funding options.
Diversified Commercial + Collaboration Revenue ModelA revenue mix of direct product sales plus collaboration/licensing and milestone streams provides multiple durable funding channels. This reduces reliance on a single product launch and enables milestone-driven cash inflections, improving strategic optionality over many months.
Integrated In‑house R&D, Manufacturing And CommercializationOwning end‑to‑end capabilities from R&D to manufacturing and commercialization is a structural advantage: it can accelerate time-to-market, lower partner dependency, and retain greater margin capture on successful assets, improving long-term program economics and negotiating leverage.
Bears Say
Collapsed Revenue TrendA dramatic multi-year revenue collapse signals loss of commercial traction or product disruptions; this structural decline weakens ability to absorb fixed R&D and manufacturing costs, undermines pricing power and partner leverage, and raises sustainable-revenue uncertainty over coming quarters.
Persistent Negative Operating Cash Flow And Accelerating BurnConsistent negative operating and free cash flow with a sharp step‑up in 2024–2025 creates a structural financing need. Without material revenue recovery, the company will likely require financing or asset monetization, diluting shareholders or disrupting long‑term programs.
Deeply Negative Profitability; Negative Gross Profit In 2025Negative gross profit indicates the cost base exceeds revenues, a structural margin failure. That undermines any operating leverage benefits and implies the need for substantive cost restructuring, price/reimbursement changes, or portfolio rationalization to restore sustainable margins.
Ascletis Pharma, Inc. News
1672 FAQ
What was Ascletis Pharma, Inc.’s price range in the past 12 months?
Ascletis Pharma, Inc. lowest stock price was HK$8.29 and its highest was HK$19.86 in the past 12 months.
What is Ascletis Pharma, Inc.’s market cap?
Ascletis Pharma, Inc.’s market cap is HK$10.63B.
When is Ascletis Pharma, Inc.’s upcoming earnings report date?
Ascletis Pharma, Inc.’s upcoming earnings report date is Aug 24, 2026 which is in 69 days.
How were Ascletis Pharma, Inc.’s earnings last quarter?
Ascletis Pharma, Inc. released its earnings results on Mar 31, 2026. The company reported -HK$0.321 earnings per share for the quarter, the consensus estimate of -HK$0.321 by HK$0.
Is Ascletis Pharma, Inc. overvalued?
According to Wall Street analysts Ascletis Pharma, Inc.’s price is currently Undervalued.
Does Ascletis Pharma, Inc. pay dividends?
Ascletis Pharma, Inc. does not currently pay dividends.
What is Ascletis Pharma, Inc.’s EPS estimate?
Ascletis Pharma, Inc.’s EPS estimate is -0.23.
How many shares outstanding does Ascletis Pharma, Inc. have?
Ascletis Pharma, Inc. has 1,068,455,100 shares outstanding.
What happened to Ascletis Pharma, Inc.’s price movement after its last earnings report?
Ascletis Pharma, Inc. reported an EPS of -HK$0.321 in its last earnings report, expectations of -HK$0.321. Following the earnings report the stock price went down -1.129%.
Which hedge fund is a major shareholder of Ascletis Pharma, Inc.?
Currently, no hedge funds are holding shares in HK:1672
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascletis Pharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
612.66%
12-Months-Change
Fundamentals
Return on Equity
-18.93%
Trailing 12-Months
Asset Growth
1.80%
Trailing 12-Months
Company Description
Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biotechnology firm engaged in the discovery, development, manufacturing, marketing, and global distribution of pharmaceutical products, with operations spanning Mainland China and international markets. The company's commercialized offerings include the Ritonavir oral tablet, a pharmacokinetic enhancer for various oral antiviral drugs targeting viral proteases and a key component of the approved antiviral Paxlovid. It also provides ASCLEVIR and GANOVO for the management of Hepatitis C virus infections. Its robust development pipeline features ASC22, being advanced for chronic hepatitis B (CHB) and as a potential functional cure for human immunodeficiency virus; ASC42, which also targets a functional cure for CHB, in addition to primary biliary cholangitis; and ASC10 and ASC11 for COVID-19. Ascletis is significantly invested in non-alcoholic steatohepatitis (NASH) research with a range of candidates such as ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC. Furthermore, its oncology programs encompass ASC40 for recurrent glioblastoma, drug-resistant breast cancer, and KRAS mutant non-small cell lung cancer, alongside ASC61 and ASC63 for advanced solid tumors, and ASC60 for general solid tumor treatment. Interestingly, ASC40 is also being explored for acne. Established in 2013, Ascletis Pharma Inc. is headquartered in Hangzhou, People's Republic of China.
1672 Stock 12 Month Forecast
Average Price Target
HK$20.17
▲(9.15% Upside)
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---